Aflibercept
- Generic Name
- Aflibercept
- Brand Names
- Eylea, Zaltrap, Yesafili
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 862111-32-8
- Unique Ingredient Identifier
- 15C2VL427D
- Background
Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15%...
- Indication
The opthalmic agent is used for the treatment of neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP).
...
- Associated Conditions
- Branch Retinal Vein Occlusion With Macular Edema, Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Macular Edema With Central Retinal Vein Occlusions, Metastatic Colorectal Cancer (CRC), Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD), Retinopathy of Prematurity (ROP)
- Associated Therapies
- -
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
- Conditions
- Interventions
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 671
- Registration Number
- NCT03823287
- Locations
- 🇵🇱
Dobry Wzrok Sp Z O O, Gdańsk, Poland
🇵🇱Gabinet Okulistyczny Prof Edward Wylegala, Katowice, Poland
🇵🇱SPEKTRUM Osrodek Okulistyki Klinicznej, Wroclaw, Poland
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
- Conditions
- Interventions
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 658
- Registration Number
- NCT03823300
- Locations
- 🇦🇷
Centro Oftalmológico Dr. Charles S.A., Capital Federal, Argentina
🇵🇹Hospital de Sao Joao; Servico de Oftalmologia, Porto, Portugal
🇺🇸The Retina Care Center, Baltimore, Maryland, United States
Comparison of Efficacy and Safety of Mitomycin and Aflibercept Used to Support Primary Trabeculectomy.
- Conditions
- Interventions
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Medical University of Lublin
- Target Recruit Count
- 64
- Registration Number
- NCT03766425
- Locations
- 🇵🇱
Medical University of Lublin, Lublin, Lubelskie, Poland
Nutraceutical Support With Omega-3
- Conditions
- Interventions
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- Università degli Studi di Brescia
- Target Recruit Count
- 60
- Registration Number
- NCT03712670
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
- Conditions
- Interventions
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 940
- Registration Number
- NCT03622580
- Locations
- 🇺🇸
Orange County Retina Med Group, Santa Ana, California, United States
🇺🇸Kaiser Permanente Riverside Medical Center, Riverside, California, United States
🇺🇸Cumberland Valley Retina PC, Hagerstown, Maryland, United States
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 951
- Registration Number
- NCT03622593
- Locations
- 🇨🇦
Toronto Retina Institute, Toronto, Ontario, Canada
🇨🇦Unity Health Toronto, Toronto, Ontario, Canada
🇺🇸Retina Consultants of Nevada, Las Vegas, Nevada, United States
A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 360
- Registration Number
- NCT03481660
- Locations
- 🇹🇷
Novartis Investigative Site, Kocaeli, Turkey
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 566
- Registration Number
- NCT03481634
- Locations
- 🇬🇧
Novartis Investigative Site, Nottingham, United Kingdom
Treatment of Macular Edema After Cataract Surgery with Subconjunctival Aflibercept
- First Posted Date
- 2018-01-11
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Tufts Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT03396861
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
Aflibercept in Patients With Pigment Epithelial Detachments (PED)
- Conditions
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2018-08-06
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 18
- Registration Number
- NCT03370380
- Locations
- 🇩🇪
University Hospital Muenster, Muenster, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.